Vir Biotechnology公司宣布，将在2026年欧洲肝脏研究学会大会上，公布其针对丁型肝炎的SOLSTICE二期临床试验第96周的完整数据。这一关键数据的发布，标志着该疗法长期疗效与安全性的评估进入了一个重要阶段，有望为丁肝治疗领域带来新的进展。业界期待通过此次数据，更深入地了解该候选药物的持续效果与潜力。
Vir Biotechnology公司宣布，将在2026年欧洲肝脏研究学会大会上，公布其针对丁型肝炎的SOLSTICE二期临床试验第96周的完整数据。这一关键数据的发布，标志着该疗法长期疗效与安全性的评估进入了一个重要阶段，有望为丁肝治疗领域带来新的进展。业界期待通过此次数据，更深入地了解该候选药物的持续效果与潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.